Our Purpose
This is Almirall's legacy for future generations, it is our contribution to society.
OUR DNA
R&D - therapeutical areas: Derma
We are driven by science, diligent by nature. Our medicines help to make a significant difference to patients’ lives by treating a wide of range of skin diseases.
INTERNATIONAL PRESENCE
A global company close at hand
Almirall has consolidated international coverage on a global scale thanks to owned subsidiaries and sales agreements with the most prestigious partners in key markets such as the USA, Japan and China.
14Affiliates in EU & US
19Countries with direct presence
+100Countries with partnership agreements
Our global presence
We are where you need us to be
Our extensive product portfolio is available in more than 100 countries – either through the 15 affiliates or via the network of strategic partnerships that we have developed over time. Our focus is global and since our beginnings we have grown our coverage to be where you need us to be.
Spain
Almirall, S.A.
General Mitre, 151
08022 Barcelona - España
+34 93 291 30 00
United States
Almirall, LLC – U.S.
101 Lindenwood,
Dr., Suite 400
19355 Malvern, PA
USA
Poland
Almirall Sp. z o.o.
Ul Pileckiego 63
02-781 Warszawa
Polska
+48- 22 330 0257
Portugal
Almirall - Produtos Farmacêuticos, Lda.
Rua do Central Park
Edificio 3, numero 6, 4B
2795-242 Linda A Velha
Portugal
+351 214 155750
Italy
Almirall, S.p.A.
Via Messina, 38 Torre C
20154 - Milano
Italia
+39 02 34 618 1
Switzerland
Almirall AG
Alte Winterthurerstrasse 14
CH-8304 Wallisellen
Schweiz
+41 (0) 44 834 9000
France
Almirall SAS
Immeuble Dueo
5 boulevard Gallieni
92130 Issy-les-Moulineaux
+33 01 46 46 19 20
United Kingdom
Almirall Ltd
Harman House
1 George St
Uxbridge
Middlesex UB8 1QQ
United Kingdom
+44 (0)20 7160 2500
Belgium
Almirall NV
Arianelaan 5
1200 Brussels
Belgique
+32 2 771 86 37
Netherlands
Almirall B.V.
Papendorpseweg 100
3528 BJ Utrecht, Netherlands
+31 - 30 799 1155
Germany
Almirall Hermal GmbH
Scholtzstraße 3
21465 Reinbek
Deutschland
+49 (0) 40 727 04-0
Nordics
Vandtårnsvej 77
2860 Søborg
Denmark
+45 70257575
Austria
Almirall GmbH
Breitenfurter Str. 113, Top 101
A-1120 Vienna
Österreich
+43 (0) 1 595 39 60
Czechia
Pujmanové 1753/10a. Praha 4
140 00, Czech Republic
Slovakia
Kalinčiakova 33A, 831 04 Bratislava
OUR STRUCTURE
Almirall’s Leadership and Governance
As a publicly listed company and for the benefit of both the financial markets and the general public, Almirall pursues an open and active information policy.
Our history
Almirall has been caring for people since 1944
1944
Our company was founded in Barcelona
1984
We develop and launched a leading antacid treatment
1990
We progress in the field of antihistamics in Spain and we started licencing our products internationally.
2000
We obtain the U.S. Food and Drug Administration (FDA) approval for an own R&D antimigraine treatment.
2007
We acquired Hermal, a European skincare business previously owned by Reckitt Benckiser.
2013
Aqua Pharmaceuticals, a North American skincare company, was acquired.
2015
We continued our acquisition strategy in skincare by buying Poli Group, world leader in nail and skin diseases.
2017
In June of that year, the European Commission approved a new Fumaric Acid Ester of our own R&D to treat psoriasis. In December, same year, we announced a collaboration agreement to develop a treatment for actinic keratosis and other skin conditions, both in Europe and the USA.
2019
In January of that year, our US subsidiary announced the launch of the first antibiotic treatment specifically developed for acne. We also obtained the rights for developing a humanized monoclonal antibody in Europe for the treatment of atopic dermatitis.
1960
We began activities in research and development
1987
We became the Pharmaceutical Industry Spanish market leader
1997
We created Almirall Prodesfarma Laboratories as a result of the merger between Almirall and Prodesfarma Pharmaceutical Groups.
2005
We gained the commercial rights for distributing a cannabinoid based medicine in Europe, for patients with Multiple Sclerosis.
2012
The EMA and the FDA approves the commercialization of Almirall's bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) in Europe and the USA.
2014
We transferred the rights for our respiratory franchise to the AstraZeneca company.
2016
Sun Pharmaceutical Industries signed an agreement with us to develop and commercialise a new biological treatment for psoriasis in Europe.
2018
We reached an agreement with Allergan to acquire five products from their US skincare business to treat acne and dermatosis.
Our responsibility
Almirall is committed to working with you on a basis of respect and integrity. We understand there are many people affected by what we do, including patients, healthcare professionals, our partners, peers and other stakeholders.
Learn more about our commitmentsYou might be interested in...
Caring of your skin
We put ourselves in your shoes to understand your conditions.